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Abstract 
To address uncertainties in the prevention and management of influenza in people with 
asthma, we performed a scoping review of the published literature on influenza burden; 
current vaccine recommendations; vaccination coverage; immunogenicity, efficacy, 
effectiveness and safety of influenza vaccines; and the benefits of antiviral drugs in 
people with asthma. We found significant variation in the reported rates of influenza 
detection in individuals with acute asthma exacerbations making it unclear to what 
degree influenza causes exacerbations of underlying asthma. The strongest evidence 
of an association was seen in studies of children. Countries in the European Union 
currently recommend influenza vaccination of adults with asthma; however, coverage 
varied between regions. Coverage was lower among children with asthma. Limited 
data suggest that good seroprotection and seroconversion can be achieved in both 
children and adults with asthma and that vaccination confers a degree of protection 
against influenza illness and asthma related morbidity to children with asthma. There 
were insufficient data to determine efficacy in adults. Overall, influenza vaccines 
appeared to be safe for people with asthma. We identify knowledge gaps and make 
recommendations on future research needs in relation to influenza in patients with 
asthma.  
 
Introduction 
Asthma is a heterogeneous chronic inflammatory lung disease characterized by 
intermittent airflow obstruction and increased reactivity to bronchoconstrictive triggers. 
Presently, an estimated 300 million people worldwide suffer from asthma (1). In 
Europe, more than 30 million people are affected, with six million suffering severe 
symptoms and 1.5 million life-threatening attacks (2). Asthma onset and acute asthma 
exacerbations (ΑΑΕ) have been strongly associated with respiratory viral and (to a 
lesser extent) bacterial infections (3-11) 
Influenza viruses cause respiratory infections, typically during winter months. Most 
significant disease is caused by influenza A and B, which may escape immune 
pressure by undergoing antigenic drift and recombination; such genetic changes lead 
to new subtypes, which can cause epidemic or pandemic outbreaks (12, 13). Each 
year, influenza virus infection affects 5 to 20% of the global population (14), while 
annual vaccination greatly contributes to reduce related morbidity and mortality (15). 
Upon vaccination, coordinated activity of innate and adaptive immune responses leads 
to generation of short- and long-lived antibody producing plasma cells and memory B 
cells. The importance of influenza as a cause of serious illness and AAE is increasingly 
appreciated (16, 17). Despite uncertainties about their effectiveness, influenza 
vaccines are widely recommended for those with asthma (18).  
To address uncertainties over the prevention and management of influenza in patients 
with asthma, we performed a scoping review and discuss the current knowledge of the 
burden imposed by influenza on patients with asthma, current vaccine 
recommendations and vaccination coverage in various regions, the evidence 
regarding immunogenicity, efficacy, effectiveness and safety of influenza vaccines, 
and the possible benefits of antiviral drugs in patients with asthma. We conclude by 
identifying knowledge gaps and future research needs in relation to influenza in asthma 
patients.  
 
1. Methods  
We systematically searched relevant published, unpublished and in-progress original 
research and systematic reviews that were pertinent to the subject matter of this EAACI 
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Task Force. This involved searching databases of peer-reviewed published literature 
(Cochrane Library, EMBASE and CINAHL, MEDLINE and Google Scholar) and 
research in progress (i.e. http://www.controlled-trials.com/ and 
http://www.clinicaltrials.gov/) for the period 2000–2015. In addition, we wrote to a panel 
of international experts in an attempt to identify additional unpublished or in-progress 
work. There were no restrictions on language of publication.  
We were particularly interested in randomized controlled trials (RCTs) on questions 
relating to the immunogenicity, efficacy and/or effectiveness of influenza vaccine 
among asthmatics, and epidemiological studies relating to the influenza 
incidence/prevalence and public health burden and safety of influenza vaccine. 
Systematic reviews with or without meta-analysis were of interest if they focused on 
any of the questions of interest.  
The searches (see Appendix 1) were undertaken and allocated to relevant sub-group 
leads depending on the focus of the inquiry. Where possible, studies reported in 
languages other than English were translated. Within subgroups, two reviewers 
independently reviewed the titles and if necessary abstracts of potentially eligible 
studies to decide on eligibility; disagreements on study eligibility were resolved through 
discussion among the reviewers. Studies were then – in the specific context of 
asthma/allergy – categorized by topic area, namely: i) Global burden of influenza; ii) 
Influenza vaccination recommendations and coverage; iii) Immunogenicity of influenza 
vaccines; iv) Efficacy of influenza vaccines; v) Effectiveness of influenza vaccines; vi). 
Safety of influenza vaccines; and vii). Antiviral treatments against influenza. Reports 
were then scrutinized and interpreted by experts on the subject matter. Any 
disagreements on issues to do with interpretation were resolved through discussion. 
The searches were first conducted in 2014 and then updated in October 2015.The key 
characteristics and findings of all eligible studies were summarized in data tables, and 
the findings narratively synthesized. These are presented by topic in Table 1. 
 
2. Global burden of influenza in patients with asthma  
2a. Influenza-attributable health care utilization in asthma patients  
Asthma is the most common underlying disease in patients with influenza admitted to 
healthcare facilities, both in adults (19-33) (7.6–46% (34, 35)) and children (26, 36-47) 
(8.3–42% (48, 49)). Children with asthma accounted for a significantly larger proportion 
of those hospitalized with pandemic H1N1 than with seasonal influenza (24, 50-53). 
Asthma was also the most common comorbidity among pregnant women hospitalized 
with H1N1 infection, with a prevalence ranging from 8-33% (54-57). 
Asthma represented a risk factor for hospitalization during influenza seasons in the 
general population (58), with an OR of 2.6 (95% CI 1.6–4.0) in two Canadian studies 
(59, 60), and a relative risk (RR) of 4.47 (95% CI 1.49–13.39) in Israel (61). The same 
applied to children (47, 62, 63), where asthma conferred a 4-fold risk of hospitalization 
(USA (64), Germany (41), and Argentina (65)), with a 21-fold risk observed in South 
Korea (66). Interestingly, influenza-related hospitalization costs in children with asthma 
may be lower than in children with other chronic conditions, and were very close to 
costs in children without comorbidity (67). 
Asthma patients seemed to have a higher risk of being admitted to the intensive care 
unit (ICU) or to have a more severe disease course when hospitalized for influenza 
(26, 33, 43, 45, 50, 66, 68-70), with an OR of 4.92 (95% CI 1.38–17.33) in Argentinian 
children (69) and a RR of 15.20 (95% CI 1.16-199.63) in China >15 years of age (71). 
Severe disease was especially common in those developing pneumonia (33), but did 
not seem to be related to the severity of underlying asthma (51). In a multivariate 
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analysis of H1N1 pediatric patients, asthma was associated with increased mortality in 
ICU-admitted children and adolescents (OR 1.34, p=0.05) (68). However, a 
retrospective analysis performed in the UK on 1,520 patients showed that patients with 
asthma hospitalized because of influenza A infection were less likely to require ICU or 
die compared with those without asthma, with an OR of 0.51 (95%CI 0.36–0.72) for 
severe outcome (28). Two other studies confirmed this finding (25, 29), which may be 
even more pronounced in those with pre-admission inhaled (OR 0.34; 95% CI 0.18–
0.66) or systemic corticosteroid treatment (OR 0.36 95% CI 0.18–0.72) for asthma and 
an earlier hospital admission (within 4 days from symptom onset - adjusted OR 0.60 
95%CI 0.38–0.94) (28). 
 
2b. Influenza-induced acute asthma exacerbations 
Influenza, like other respiratory viral infections, can lead to AAE and was found to 
account for 32.0% (72) and 9.8% (73) of AAEs in two studies of adults with  asthma 
outpatients. However, the method used to identify the presence of influenza in AAE 
episodes largely determines the outcome. A direct comparison of molecular (PCR), 
serological, and immunofluorescent (IFA) detection in the same cohort of adults with 
asthma found influenza rates of 24.0%, 18.3%, and 2.0% respectively in AAEs (74). 
Thus, the validity of studies that applied conventional influenza identification 
techniques such as cytopathic effect in cell culture followed by indirect 
immunofluoresence to confirm viral presence (75) is questionable. Among hospitalized 
adults with asthma patients, rates of influenza-induced AAE were reported at 10.0% 
(76), 19.0% (77), 20.7% (78), and as high as 37.9% (73).  
Available data on influenza-associated AAE among children vary considerably. For 
outpatient visits, three studies did not detect any influenza-positive samples (75, 79, 
80), while several groups identified influenza infection as the cause of AAE, with most 
reporting rates of influenza-positive samples between 2.4% and 15.5% (63, 81-84). A 
recent study showed an accentuated propensity for loss of asthma control when 
children were infected with pH1N1 (38%) compared with other common respiratory 
virus infections (85). Among children with asthma hospitalized for severe AAE, three 
studies reported an influenza-associated burden of 2.6% (82), 3.4% (86) and 3.7% 
(63) of AAEs. In summary, there were significant inter- and intra-group variations in 
the reported influenza-induced AAE burden among children and adults with asthma, 
with fewer studies on adults.  
Various factors compromise the interpretation of the available data. First, the use of 
different diagnostic methods for influenza detection may significantly influence the 
study outcome. The advent of molecular techniques and their universal use may solve 
this issue. Second, the absence of harmonized criteria for appropriate inclusion of 
patients and the lack of a standardized definition and diagnosis of influenza infection 
disallow direct comparison of results and complicate the identification of relevant 
studies. Third, the lack of large cohorts of patients with asthma studied for influenza 
induced AAE, raises questions about the validity of the currently available findings. 
Furthermore, seasonal rather than perennial influenza testing and selective testing 
only in hospitalized AAE cases could lead to inaccurate estimation of the actual 
contribution of influenza to AAEs.  
 
3. Current influenza vaccine recommendations and coverage for people with 
asthma  
In common with most economically-developed nations (Fig. 1), all 28 countries of the 
European Union currently recommend influenza vaccination of people with chronic 
respiratory disease, including asthma (87-89). Trivalent (TIV) and quadrivalent 
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inactivated split-virus influenza vaccines are available, with TIV the most widely used 
throughout the EU. An intradermal vaccine is also available and more recently a 
quadrivalent live attenuated intranasal vaccine (LAIV) was approved for use in the UK 
in children aged 2–18 years (88, 90).  
However, vaccine uptake for clinical risk groups varied from 31% in Portugal to 82% 
in Northern Ireland (88, 91), as did influenza vaccination coverage of adults with 
asthma, with 30–50% in Spain (92-95) and 40% in the UK (96). Self-reported uptake 
of seasonal influenza vaccine amongst adults with asthma in the US varied from 54% 
in the community to 71% in secondary care (97). Children with asthma had significantly 
lower coverage rates of approximately 18-20% in Spain (93, 98), 15% in France (99) 
and 2.5–20% in Italy, across multiple seasons (91). In comparison, in the USA 
vaccination coverage reached around 50% in adults and children (100).  
To address the question of such historically low vaccination rates amongst those with 
asthma, many studies employed cross-sectional surveys to analyse the socio-
demographic variables that predict vaccine uptake. The strongest factors associated 
with higher vaccine coverage, were older age, recent contact with healthcare 
providers, non-smoking status, presence of co-morbidities, more severe asthma, and 
(surprisingly) lower household income (92-95, 100-106), although regarding there are 
conflicting reports for the latter (98). Variables that were associated with lower 
vaccination uptake included younger age groups (96, 100, 107, 108), belonging to 
certain ethnic groups (102, 105, 108) and lack of awareness about the vaccine (91, 
99, 100). A more detailed exploration assessing health attitudes suggested that the 
misbelief that the vaccination was not necessary or could actually cause influenza or 
side effects was predictive of non-adherence (97, 109-112) and contributed to lower 
vaccination coverage (96, 107, 108). Reports of low effectiveness probably also 
contributed to poor uptake (18, 113, 114). 
Healthcare worker endorsement of vaccination was highly predictive of adherence 
(109, 110, 112). A survey of 1225 US allergists suggested that 85% of these offered 
influenza vaccinations to adults and children. Younger allergists (<45 years) were more 
likely to offer vaccination, especially to children (115). Pediatricians were more likely 
than family physicians to routinely recommend influenza vaccination to children with 
asthma (adjusted OR 3.49, 95% CI 1.68-7.22), with decisions also being made 
depending on asthma phenotype (i.e. intermittent vs. persistent) (116). 
The success of vaccination programmes was affected by complex factors such as the 
nature of healthcare provision (e.g. free care or insurance based), education levels, 
and cultural acceptance of the vaccine. Therefore, national health surveys with 
information on vaccination status linked with medical and socio-demographic details, 
(such as that of Spain with data spanning more than two decades (92-95, 117) can aid 
in assessing the impact of influenza vaccination, at population level. 
Simple interventions such as allowing for year-round scheduling of appointments for 
vaccination can be effective (118). Nevertheless, it is likely that only major policy shifts 
will lead to significantly higher vaccination rates, due to more clear and consistent 
messaging about the importance and acceptability of influenza vaccination to patients 
and healthcare workers alike. This is illustrated by the increase in influenza vaccination 
uptake among children with asthma from 36% (2005–2006) to 50% (2010–2011) after 
the US Centre for Disease Control and prevention (CDC) advised vaccinating all 
children, regardless of risk (100). With its favourable safety and cost-benefit profile (18, 
119, 120) there is a need for health campaigns to raise awareness amongst the public 
and clinicians of the benefits of influenza vaccination and to improve implementation 
of guidelines. 
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4. Immunogenicity of influenza vaccines in asthma  
There is uncertainty about the level of protection that influenza vaccines afford in 
people with asthma. Influenza vaccine immunogenicity, a prerequisite for protection, 
is usually assessed by haemagglutinin inhibition assay (HI) measuring seroprotection 
rate (percentage of subjects with antibody titres ≥1:40), seroconversion rate 
(percentage of subjects with ≥4-fold increase in antibody titre), antibody geometric 
mean titre (GMT), and GMT ratio (GMT post vaccination/GMT pre-vaccination).  
We identified limited data on influenza vaccine immunogenicity in asthma. Only one 
study of TIV in children aged 0.5–3 years compared healthy controls to recurrent 
wheezers. It found good and similar seroconversion and seroprotection rates to all 
three vaccine strains (H1N1, H3N2, and B) in both groups (after 1 month), with higher 
pre-and post-vaccination GMTs in children with wheeze, but a higher GMT ratio in 
healthy controls (121). In children with asthma, TIV and a virosomal inactivated subunit 
influenza vaccine induced good seroprotection and seroconversion at 1 month in both 
pre-school and school-age children, with some reduction in GMTs by 6 months (122, 
123). A 2009 H1N1 vaccine given to adolescents and adults induced equally good 
seroprotection if 15 µg or 30 µg vaccine were given in those with mild-to-moderate 
asthma. In contrast, in severe asthma the higher dose resulted in better seroprotection, 
which in elderly severe asthma patients (≥60 years) was only achieved with the high 
30 µg dose (124). In the latter group and in young children with recurrent wheeze, 
corticosteroid treatment or corticosteroid dose did not influence influenza vaccine 
immunogenicity (121, 124).  
 
5. Efficacy of influenza vaccines in asthma 
Data on the efficacy of influenza vaccination in asthma are limited, with only two 
randomized studies addressing the efficacy of TIV in patients with stable asthma. One 
study, conducted in Turkey, included 128 adults with asthma who received either TIV 
or no vaccination (125). No significant difference in the frequency of upper respiratory 
tract infections (URTI) or AAE rate was found between vaccinated and non-vaccinated 
participants; however, this study had significant limitations (see Table 1). In a larger 
randomized, double-blind, placebo-controlled trial from the Netherlands (81) in 6–18 
year-old children with asthma, TIV had no significant effect on the number, severity, or 
duration of AAEs caused by confirmed influenza infection, or on the respiratory 
symptoms recorded; however, it moderately improved quality of life during the weeks 
of inﬂuenza-positive illness (126). In contrast, a conference abstract (127) reported 
significantly lower AAE rates in children <5 years with asthma following TIV (13%) 
compared with placebo (53%). 
 
For LAIV, we found no efficacy data in asthma compared to non-vaccination. A large 
European multi-center, randomized, open-label trial compared intranasal cold-adapted 
LAIV to intramuscular TIV in children and adolescents aged 6–17 years with asthma, 
and reported a 34.7% reduction in culture-conﬁrmed inﬂuenza illness after LAIV (128). 
A re-analysis of efficacy data from two randomized, multinational trials (129, 130) 
comparing LAIV to TIV, demonstrated that 2–5 year old children with mild-to-moderate 
asthma or prior wheezing, receiving LAIV had fewer cases of culture-confirmed 
influenza illness than TIV recipients (131). 
 
 
6. Effectiveness of influenza vaccination in asthma  
While efficacy studies reflect a treatment’s performance in tightly controlled clinical 
trials, effectiveness studies reflect how well a treatment works in practice and are more 
representative of real life. Influenza vaccination may be less effective than expected 
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due to differences between the characteristics of patients vaccinated in the general 
population and those recruited into efficacy trials. Furthermore, the influenza vaccine 
may not contain the prevalent virus strain, and vaccine coverage may be suboptimal.  
There are limited data on the effectiveness of influenza vaccination in patients with 
asthma or high-risk populations that included asthma. Six studies assessed the 
effectiveness of seasonal influenza vaccines, while one other studied the H1N1 
pandemic vaccine (132).  
In children, two retrospective cohort studies found that influenza vaccination was 
associated with a reduction in the rate of asthma exacerbations (133) and fewer acute 
respiratory problems (only in those less than 6 years of age) (134). A survey found that 
vaccination in children with asthma was associated with less use of rescue 
prednisolone (135), while a nested case-control study suggested that influenza 
vaccination was associated with fewer acute general practice visits for respiratory 
problems in children with long-term conditions (136). However, another case-control 
study suggested that vaccination was associated with an increased risk of 
unscheduled attendance for asthma care (137). In this study, the cases and controls 
were poorly balanced in terms of ethnicity and likelihood of vaccination in previous 
years. Although an adjusted analysis was undertaken, this may not have taken into 
account all the differences between the groups. 
Only one study focused on adults with asthma (132). In this study, the H1N1 influenza 
vaccine was found to be protective against influenza in those aged under 61 years, but 
not in older patients. Also, it did not protect against AAE. Two other studies enrolled 
adults with long-term (136) or high-risk conditions (138); the first demonstrated a 
reduction in general practice visits, hospitalization and deaths from respiratory 
problems, while the second demonstrated a protective effect against influenza and 
influenza related hospitalization. Asthma was not analysed separately in these studies 
and it is thus not clear if influenza vaccination was beneficial for people with asthma. 
A recent systematic review reports a 59-78% reduction in asthma attacks leading to 
emergency visits and/or hospitalizations after influenza vaccination and a vaccine 
effectiveness of 45% (95% CI 31 to 56) for laboratory-confirmed influenza in people 
with asthma based on a metanalysis of two test-negative design case-control studies 
(139).   
 
7. Safety of influenza vaccines in asthma  
Large retrospective and prospective studies have demonstrated the safety of influenza 
vaccines in children and adults with asthma, for both TIV and LAIV (131, 140-142). In 
these studies, vaccinated patients did not have more frequent asthma exacerbations 
than unvaccinated patients, and no other adverse event was more common in 
asthmatics. A study of adult asthma patients who reported bronchospasm after 
influenza vaccination, indicated that these symptoms were not related to vaccine 
hypersensitivity (143). 
A common concern is the safety of egg-derived influenza vaccines in patients with egg-
allergy, a frequent co-morbidity in children with asthma. The last case of anaphylaxis 
after influenza vaccination occurred more than 25 years ago at a time when the egg 
content of vaccines was much higher. The ovalbumin content of most current vaccines 
is less than 1.2 μg/mL, and an egg-free influenza vaccine is also available. Several 
studies demonstrated that influenza vaccines containing low levels of egg protein 
(≤1.2mμg/mL) were safe even in egg-allergic patients (143-149). This also seemed to 
be true in egg-allergic patients with associated asthma. The recent SNIFFLE studies 
of LAIV in egg allergic children, including 634 children with asthma/recurrent wheeze 
(79.7% on daily inhaled corticosteroid treatment), found no immediate systemic allergic 
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reactions (150, 151). For 6.6% of children with asthma/recurrent wheeze, the parents 
reported wheeze within 72 hours of LAIV, but most wheeze episodes only required 
routine treatment; there was no hospitalization and no increase in respiratory 
symptoms in the four weeks after LAIV.  
Based on the robust evidence that influenza vaccines are safe in asthma patients with 
and without egg allergy, British immunization guidelines (152) now recommend 
administration of LAIV in the community to children from 2 years of age, including those 
with asthma, irrespective of egg allergy, unless they have severe or acutely 
exacerbated asthma. US and Canadian guidelines remain more conservative and still 
suggest that vaccines containing egg proteins (e.g. LAIV) should not be used in 
children with egg allergy and/or asthma (153-155). 
 
8. Antiviral treatment against influenza in patients with asthma 
For asthma patients with suspected influenza infection, treatment with antiviral 
medication as early as possible, prior to laboratory confirmation of influenza, is 
currently recommended (156-160). Since amantadine and rimantadine are limited by 
drug resistance, they have been replaced by neuraminidase inhibitors (NI). The 
currently marketed NIs are zanamivir and oseltamivir. However, post-marketing 
surveillance has revealed bronchospasm and worsening of lung function in a few cases 
when asthma patients were treated with zanamivir inhalation (161). Therefore, the 
manufacturer does now not recommend zanamivir for patients with chronic respiratory 
disease, including asthma (157, 158). Oseltamivir was not associated with any 
significant respiratory adverse effects and is recommended for treatment and 
chemoprophylaxis of influenza in children and adults with high-risk chronic conditions, 
including asthma (162-164). However, large-scale telephone surveys in the USA 
showed that having asthma, in contrast to diabetes, was not associated with increased 
rates of antiviral treatment of influenza cases (165).  
Data on the efficacy of NI in asthma patients (162, 166-168) are limited. A benefit of 
oseltamivir treatment was found in children in an RCT that showed significantly 
improved pulmonary function and fewer AAEs (168). A meta-analysis, based on a 
single RCT, reported improved FEV1 after oral oseltamivir given to children with 
asthma and influenza infection, but no effects on peak flow or AAEs (169). Two recent 
systematic reviews found that oseltamivir relieved influenza symptoms in otherwise 
healthy children, but had no effect on children with asthma who have influenza-like 
illness (170, 171), a finding that is currently controversial.  
As high rates of resistance limit the effectiveness of the currently available antiviral 
drugs, new NI (laninamivir, peramivir) and an RNA-dependent RNA polymerase 
inhibitor (favipiravir) are currently undergoing clinical trials (172). Laninamivir showed 
similar efficacy and safety to oseltamivir in the treatment of influenza in asthma patients 
(173). 
 
9. Conclusions 
We observed significant variation in the reported rates of influenza detection among 
AAE episodes in both children and adults, with higher rates observed in the latter age 
group. This may be attributed to major differences in inclusion criteria, disease 
definitions, virus detection methodology, small population sizes and the limited number 
of available studies. Therefore, it is presently unclear to what degree influenza causes 
exacerbation of underlying asthma.  
All European Union countries currently recommend influenza vaccination of people 
with asthma, with TIV being the most widely used vaccine. Nonetheless, vaccination 
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coverage varies between regions, and is significantly lower among children with 
asthma. Several factors and misbeliefs have been shown to predict non-adherence to 
influenza vaccination, while healthcare worker endorsement highly promotes 
vaccination. Major policy shifts and health campaigns may help in raising awareness 
and improve guideline implementation. 
The limited immunogenicity data suggest that good seroprotection and seroconversion 
can be achieved in children and adults with asthma. However, higher vaccine doses 
may be required in elderly patients. Available studies suggest increased efficacy of 
LAIV in reducing influenza illness in children/adolescents with asthma compared to 
TIV, but do not provide evidence of efficacy of TIV in reducing influenza illness in 
asthmatics concurring with a recent systematic review (18).  
There are some limited data to suggest that influenza vaccination reduces asthma-
related morbidity in children in real-life settings, as has been concluded in another 
recent systematic review (139). The only data to suggest that vaccination may have a 
beneficial impact in adults with asthma are from studies of patients with long-term or 
high-risk conditions, not just asthma. The effectiveness outcomes of these studies are 
difficult to interpret due to lack of an agreed definition for asthma and/or influenza, and 
insufficient information on the type of vaccination used. Lack of randomization is also 
a limitation, as differences in the characteristics of those who do and do not receive 
the vaccine, such as disease severity and socioeconomic status, may independently 
impact on the likelihood of asthma morbidity, and analyses may not control for all these 
differences. Despite these limitations, population-based effectiveness studies are the 
only way to assess the impact of vaccination in real-life healthcare settings.  
Inactivated influenza vaccines appear to be safe for people with asthma, and, provided 
they have low egg protein content (≤1.2 μg/mL), also for those with egg allergy. LAIV 
is also safe in asthma and egg allergy with the exception of severe or acutely 
exacerbated asthma, where LAIV cannot be given. Oseltamivir is the NI that is 
currently used in asthma. Although it has moderately beneficial effects on influenza 
illness in healthy people, there are insufficient data to determine its efficacy and 
effectiveness in people with asthma. However, novel NIs are currently in development.  
 
10. Recommendations and future needs 
People with asthma are at high risk of more severe forms of influenza, with increased 
hospitalization and admission at healthcare facilities, therefore: 
 Education campaigns for both the general population and healthcare providers are 
needed to promote an increase in annual influenza vaccination, early case 
recognition and consideration of early empirical antiviral therapy, and to reduce 
influenza-attributable healthcare utilization among asthmatics. 
 Large cohort and case control studies using standardized definitions (for AAE), 
sensitive influenza detection methods, such as PCR, and comprehensive 
assessment of respiratory pathogens are necessary in both children and adults 
with asthma.  
 There is a need to develop more internationally co-ordinated registries, e.g. for 
Europe, that accurately collate vaccination status along with medical and socio-
demographic details to assess the impact of public health interventions over time.  
 Multiple sources of data must be used to record vaccination status (e.g. self-
reported as well as medical notes, vaccination card or billing data).  
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 Targeted vaccination of children and at-risk groups is needed. 
 Further studies of influenza vaccine immunogenicity, comparing healthy and 
asthmatic populations, are required to determine if people with asthma have 
normal influenza vaccine responses or if they require influenza vaccines with 
enhanced immunogenicity. The discovery and development of improved immune 
correlates of protection against influenza will enable more meaningful testing of 
vaccine immunogenicity.  
 In view of the uncertainty around the degree of protection that influenza vaccination 
affords in people of all ages with asthma, further efficacy data need to be collected 
in this population. Data should be stratified by age and asthma severity, using 
adequately powered, randomised, placebo-controlled trials that compare both TIV 
and LAIV to non-vaccinated controls.  
 Further studies are needed to evaluate the effectiveness of influenza vaccination 
in patients with asthma, but must be designed to minimize any risk of bias.  
 Safety data in asthma with and without egg allergy are required for new influenza 
vaccines, and, depending on egg protein content, for new LAIV batches. 
 There is a need to collect more safety data on zanamivir in patients with chronic 
respiratory disease, and efficacy data on oseltamivir in children with asthma.  
 Development and testing of new anti-influenza drugs among asthmatics is needed.  
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 Table 1. Studies included in the systematic review, by section 
 
Section 2a. Influenza-attributable health care utilization in asthma patients   
Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
Chacon et al. 
2015 (174) 
Guatemala  May 2009 - 
June 2010 
Epidemiological 
retrospective 
study 
NA Demographic and clinical 
characteristics of deaths 
associated with influenza 
A (H1N1) pdm09. 
History of Asthma in 11% 
of the 112 dead patients 
with a pre-existing medical 
condition (7% children < 5 
years, 11% people aged 5-
59, 16% people aged 60+ 
and 18% of the 14 dead 
pregnant or postpartum 
women) 
183 children and 
adults aged 0-60+ 
years. SARI 
decedents who 
tested positive for 
influenza. 
Study 
performed in 
seven Central 
America 
Countries. 
Dawood et al. 
2014 (49) 
USA 2003-2009 
(seasonal) 
2009-2010 
(H1N1) 
Epidemiological 
retrospective, 
population-
based study 
NA Frequency and severity 
of influenza 
complications in 
hospitalized children. 
History of asthma in 31% 
of children hospitalized for 
seasonal influenza vs. 42% 
in children hospitalized for 
influenza A (H1N1). 
Asthma exacerbation as a 
complication in 27% of 
children with influenza A 
vs. 18% in children with 
seasonal influenza (overall, 
22% of total). 
6769 children and 
adolescents aged 
<18 years 
hospitalized for 
both seasonal and 
H1N1 influenza. 
 
Hagerman et al. 
2015 (175) 
Switzerland June 2009 
- Jan 2010 
Prospective/ 
retrospective 
study performed 
in 11 hospitals 
NA Clinical characteristics of 
the influenza-hospitalized 
children. 
Asthma 12% among the 
comorbidities of the 126 
influenza-hospitalized 
children. 
326 patients aged 
≤18 years (189 <5 
years; 126 with 
comorbidities 
hospitalized in 
eleven children’s 
hospitals in 
Switzerland with a 
positive influenza 
A/H1N1/09 RT-
PCR from a 
Study 
performed in 
11 hospitals in 
Switzerland. 
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Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
nasopharyngeal 
specimen. 
Jiang et al. 
2015 (71) 
China Dec 2008 - 
June 2014 
Epidemiological 
retrospective 
study 
NA Clinical characteristics 
and severe case risk 
factors for adult inpatient 
cases of confirmed 
influenza. 
  
Out of the 240 (7.8%) 
cases of laboratory-
confirmed influenza, (H1N, 
pdm2009 and H3N2), 
asthma was the most 
important risk factor for 
severe cases (RR = 
15.200, 95% CI: 1.157-
199.633). 
240 adults aged 
≥15 years 
consistent 
with SARI case 
definition who 
were monitored 
by SARI sentinel 
hospitals in ten 
cities in China. 
Data 
extrapolated 
from abstract 
in English. 
Study 
performed in 
ten provinces 
of China. 
Kwon et al. 
2014 (176) 
South Korea May 2010 -
Apr 2011 
Retrospective 
study 
NA Prevalence of year-round 
respiratory viral infection 
in children with LRTI and 
the relationship between 
respiratory viral infection 
and allergen sensitization 
in exacerbating asthma. 
Influenza virus was 
detected in 7 (25%) of the 
28 asthma patients 
hospitalized for asthma 
exacerbation. 
18 asthmatics (64.3%) had 
atopic sensitization. 
Influenza virus responsible 
for asthma exacerbations 
with an OR 11.9 (1.5-90.4) 
for atopic asthma), 0.9 
(0.1-12.3) for non-atopic 
asthma, 4.0 (1.2-13.8) for 
asthma in general. 
 
309 children 
(median age 26 
months) who were 
hospitalized for 
acute LRTIs 
(pneumonia, 
bronchitis, 
bronchiolitis or 
asthma). 
 
Park et al. 2013 
(177) 
South Korea Jan - Dec 
2009 
Multi-site case-
control study 
NA Association of asthma 
status and severity of 
H1N1 influenza in adults. 
Of the 91 cases, 12(13%) 
and 3 of 54 controls (5%) 
were asthmatics (p=NS); of 
those without other 
comorbidities except 
asthma, 8 of 56 cases 
(14%) and 2 of 49 (4%) 
91 cases 
(47.3±21.1 years) 
with a positive 
PCR for H1N1 
influenza and 
were admitted to 
the ICU or general 
ward with a 
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Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
controls had asthma 
(p=NS). 
diagnosis of H1N1 
influenza. 
56 controls 
(45.0±20.6 years) 
with a positive 
PCR for H1N1 
influenza, but 
were not admitted 
to hospitals. 
 
Placzek et al. 
2014 (178) 
USA Oct 2008 - 
Apr 2009 
(seasonal 
influenza) 
Apr 2009 -
Sept 2009 
(H1N1) 
Epidemiological 
retrospective 
study 
NA Association of age and 
comorbidity on 2008-
2009 seasonal influenza 
and 2009 Influenza A 
(H1N1)-related ICU stay. 
Asthma was the most 
prevalent risk factor for 
hospitalization, occurring in 
28% (n=148) of the pH1N1 
population, and 24% 
(n=174) of those with 
seasonal influenza. 
1254 children and 
adults aged <5-64 
years with 
seasonal and 
H1N1 influenza 
admitted to an 
ICU. 
 
Stripeli et al. 
2015 (179) 
Greece Oct 2009 - 
Feb 2010 
and 
Jan 2011 - 
May 2011 
(pH1N1) 
2002 -2003 
and 2004 -
2005 
(Influenza 
A) 
Epidemiological 
retrospective 
study 
NA Epidemiological and 
clinical characteristics of 
children hospitalized with 
pH1N1 compared with 
those of children 
hospitalized with 
seasonal influenza A in 
previous years. 
Asthma was the most 
common underlying illness 
in both cohorts, but it was 
considerably more 
prevalent in the seasonal 
influenza group (19% vs. 
7%; P=0.048). 
146 children with 
pH1N1 aged 0-14 
years and 138 
children with 
seasonal 
influenza aged 6 
months-14 years 
who were 
hospitalized for 
both pH1N1 and 
influenza A. 
 
Taha 2014 (57) Saudi Arabia June 2009 
- Feb 2010 
Retrospective 
cohort study 
NA Characteristics of 
pregnant Women 
admitted with 2009 H1N1 
Influenza in a referral 
maternity hospital. 
Bronchial asthma was 
present in 15 (45.5%) of 
pregnant women admitted 
with influenza. 
33 pregnant 
women; mean age 
27.7±5.6 years. 
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Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
Tam et al. 2014 
(180) 
USA 2007-2011 Retrospective 
population-
based study 
(chart reviews)  
NA Influenza-related 
hospitalization of adults 
associated with low 
census tract, 
socioeconomic status 
and female sex. 
Asthma was increasingly 
prevalent among cases 
with progressively higher 
census tract poverty status 
(16.4% in low poverty vs. 
37.7% in high poverty). 
Females overall and in 
each age group were more 
likely to have asthma 
(overall, 27.6% vs. 16.7%; 
P<0.001). 
1094 hospitalized 
adults aged 18-
65+ years with 
laboratory-
confirmed 
influenza. 
 
 
ICU intensive care unit; NS not significant; LRTI lower respiratory tract infection; RR risk ratio; CI confidence interval; OR odds ratio; RT-PCR reverse transcriptase polymerase 
chain reaction; SARI severe acute respiratory infection. 
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Section 2b. Influenza-induced acute asthma exacerbations 
Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding (absolute 
number of positive 
samples) 
Population 
characteristics 
Limitations/ 
comments* 
CHILDREN 
Azevedo et al. 
2003 (75) 
Brazil ND Retrospective  NA Laboratory confirmed 
IFV/ culture and IFA 
0.0% (0) 36 children aged 
2-14 years 
 
Thumerelle et 
al. 2003 (83) 
France  
1 Oct 1998 
- 30 June 
1999 
Prospective NA Laboratory confirmed 
IFV/IFA, serology or both  
3.6% (3)  82 inpatients aged 
2-16 years 
 
Biscardi et al. 
2004 (86) 
 
France 1 Jan 1999 
- 30 June 
2001 
Prospective NA Laboratory confirmed 
IFV/culture and IFA  
3.4% (4) 119 inpatients 
aged 2-15 years 
 
0.0% (0) 51 first episode 
(initial asthma) 
Bueving et al. 
2004 (81) 
Netherlands 1999-2001 Double-blind, 
randomized, 
placebo-
controlled trial 
Inactivated 
influenza 
vaccine vs 
placebo 
Laboratory confirmed 
IFV/ culture, IFA and RT-
PCR  
7.2% (17) 235 children aged 
6-18 years 
Low number of 
IFV positive 
samples in first 
season-
compensated 
by recruitment 
of higher 
number of 
subjects in 
second season 
Johnston et al. 
2005 (79) 
Canada 10-30 Sept 
2001 
Prospective NA Laboratory confirmed 
IFV/PCR  
0.0% (0)  52 children aged 
5-15 years 
 
Ketsuriani et al. 
2007 (80) 
USA Mar 2003 - 
Feb 2004  
Prospective NA Laboratory confirmed 
IFV/PCR  
0.0% (0)  65 children aged 
2-17 years 
Modest sample 
size 
USA 2002-2004 Prospective  NA 15.5% (38)  245 outpatients  
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Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding (absolute 
number of positive 
samples) 
Population 
characteristics 
Limitations/ 
comments* 
Miller et al. 
2008 (63) 
Laboratory confirmed 
IFV/PCR or culture 
3.7% (19)  513 inpatients 
aged 6-59 months  
Vallet et al. 
2009 (84) 
France 
1 Oct 2005 
- 30 Nov 
2007 
Prospective NA Laboratory confirmed 
IFV/IFA  
2.4% (4)  166 inpatients 
aged 2-15 years 
 
Kwon et al. 
2013 (176) 
Korea Apr 2010 -
Apr 2011 
Prospective NA Laboratory confirmed 
IFV/RT-PCR 
25.0% (7) 28 inpatients aged 
60±34 months 
(Mean±SD) 
Modest sample 
size, selection 
of the study 
population, 
short duration 
(1 year) of the 
study, single 
medical center, 
and subjects 
were limited to 
children with 
LRTIs severe 
enough to 
require 
hospitalization. 
Mandelcwajg et 
al. 2010 (82) 
France Nov 2005 -
Mar 2009 
Retrospective NA Laboratory confirmed 
IFV/  
IFA 
14.0% (15)  107 outpatients  
2.6% (6)  232 inpatients 
aged 1.5-15 years 
ADULTS 
Wark et al. 
2001 (72)  
Australia/UK 2 Feb - 1 
Dec 1998 
Prospective NA Laboratory confirmed 
IFV/RT-PCR, serology, 
culture and IFA 
24% (12) 49 outpatients 
aged 16-74 years  
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Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding (absolute 
number of positive 
samples) 
Population 
characteristics 
Limitations/ 
comments* 
Simpson et al. 
2003 (74) 
Australia/UK ND Prospective NA Laboratory confirmed 
IFV/PCR or serology or 
IFA  
PCR screening: 24.0% (12)  
Serology screening: 18.4% 
(9)  
IFA screening: 2.0% (1)  
49 inpatients aged 
16-74 years 
 
Tan et al. 2003 
(78) 
Singapore ND Prospective NA Laboratory confirmed 
IFV/RT-PCR, dot blot and 
DIG-probe hybridization 
20.7% (6) 29 inpatients aged 
42±15 years 
(Mean±SD) 
Uneven sex 
distribution 
(prevalence of 
females in 
acute asthma 
group). 
Iikura et al. 
2014 (76) 
Japan May 2011-
Dec 2012 
Prospective NA Laboratory confirmed 
IFV/RT-PCR 
10.0% (5) 50 inpatients aged 
28-92 years 
Although 98% 
of patients had 
a common cold 
history 
receding their 
AAE, a 
pathogen was 
detected from 
nasopharynge
al swabs in 
only 70% of 
cases. Overall, 
15 major 
viruses and 6 
major bacteria 
were evaluated 
by multiplex 
PCR analysis. 
It is possible 
that other 
minor 
pathogens may 
be involved in 
AAE. Other 
potential 
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Authors, Year Country Study 
Period 
Type of study Intervention Outcome measure Key finding (absolute 
number of positive 
samples) 
Population 
characteristics 
Limitations/ 
comments* 
reasons for the 
low yield 
include 
inappropriate 
timing of 
sampling, 
lower 
respiratory 
tract infections, 
misinterpretatio
n of allergic 
rhinitis 
symptoms, and 
single testing 
upon 
admission. 
Teichtal et al. 
1997 (77) 
Australia Aug 1993-
July 1994 
Prospective NA Laboratory confirmed 
IFV/Culture and serology  
19.0% (15) 79 inpatients aged 
16-66 years 
 
Atmar et al. 
1998 (73) 
USA 6 Dec 
1991-3 
May 1994 
Prospective  NA Laboratory confirmed 
IFV/Culture, serology and 
RT-PCR  
37.9% (11) 29 inpatients aged 
19-50 years 
 
9 Dec 
1992-31 
May 1993 
Cross-sectional 9.8% (12) 122 outpatients 
aged 17-77 years 
*as reported in the original article 
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3a. Current influenza vaccine recommendations for people with asthma 
Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key findings Population 
characteristics 
Limitations/co
mments 
 
Grohskopf et al. 
2014 (181) 
 
USA 2013-2014 National 
Recommendatio
ns after 
reviewing 
literature based 
on GRADE 
approach 
LAIV and IIV in 
asthma 
Efficacy and safety Advise that children 
between 2-4 years who 
have asthma or wheezing 
in previous 12 months 
should not be given LAIV. 
Adults and 
children including 
those with 
asthma. 
Population size 
unavailable. 
 
 
Grohskopf et al. 
2015 (153) 
 
USA 2014 - 
2015 
National 
Recommendatio
ns after 
reviewing 
literature based 
on GRADE 
approach 
LAIV and IIV in 
asthma 
Efficacy and safety - All adults and 
children including 
those with 
asthma. 
Population size 
unavailable. 
No change 
from 2014 -
2015 
 
Byington et al. 
2014 (182) 
 
USA 2013 - 
2014 
National 
Recommendatio
ns from 
American 
Academy of 
Paediatrics 
LAIV and IIV in 
asthma 
Efficacy and safety Annual vaccination 
(trivalent or quadrivalent) 
recommended for 
everyone with special effort 
made towards asthmatics. 
Asthma present in 26% 
hospitalized children with 
confirmed influenza during 
the 2013-14 season. 
All children aged 
>6 months 
including those 
with asthma. 
Population size 
unavailable. 
 
LAIV live attenuated influenza vaccine; IIV inactivated influenza vaccine 
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Section 3b. Current influenza vaccine coverage for people with asthma 
Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key findings Population 
Characteristics 
Limitations/
comments 
Koshio et al. 
2014 (132) 
Japan Sept-Oct 
2010 
Questionnaire-
based cross-
sectional survey  
NA Receipt of H1N1 vaccine 
and infection status as 
well as recording of ACT 
score. 
Incidence of H1N1 pdm09 
infection 6.7% (95% CI 5.7–
7.6). 
Vaccine receipt in 63.9% 
(95% CI 62.1-65.8%). 
Infected patients (n=170) 
had significantly lower rates 
of vaccination, were younger 
and had experienced more 
night symptoms and sleep 
disturbance in the preceding 
2 weeks. 
2,555 asthma 
patients, aged ≥16 
years. 
Good 
characterizat
ion of 
asthmatics 
but no 
objective 
definition of 
influenza 
infection. 
Pennant et al. 
2015 (183) 
USA 2009-2015 Prospective 
interventional 
quality 
improvement 
study 
Physician 
reminders, 
patient letters, 
nurse-driven 
Change in vaccination 
uptake rate. 
Vaccine receipt improved 
from 59% to 64% between 
2011 and 2014 influenza 
seasons. 
1142 asthma 
patients in an 
allergy clinic aged 
≥13 years (85 
declined vaccine).  
 
Gnatiuc et al. 
2015 (184) 
Global (23 
countries) 
2008 
onward 
International 
cross sectional 
survey 
comparing high 
income and low-
middle income 
countries 
Participants 
with doctor 
diagnosed 
asthma 
underwent 
reversibility 
testing with 
salbutamol 
Use of respiratory 
medicines and uptake of 
influenza vaccine in 
preceding 12 months. 
Overall influenza vaccination 
uptake rates: 1.4% in LMIC 
vs. 28.4% in HIC (P = 
0.0001). 
15,590 adults with 
asthma and 
COPD, aged ≥40 
years (unclear 
what proportion 
are asthmatic). 
 
Rare 
example of 
research 
comparing 
multiple 
countries 
from across 
the income 
spectrum 
The age 
criteria for 
the study 
likely 
excluded a 
large 
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Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key findings Population 
Characteristics 
Limitations/
comments 
proportion of 
asthmatics  
Vernacchio et 
al. 2014 (185) 
USA 2009-2012 Learning 
collaborative 
model 
Regular face 
to face 
meetings and 
electronic 
communicatio
n between 
healthcare 
teams 
Uptake of influenza 
seasonal vaccination. 
Uptake of asthma action 
plans. 
Inconsistent improvements in 
rates of vaccine uptake. 
Significant increase in 
implementation of asthma 
action plans. 
594 patients with 
persistent asthma, 
aged 5-17 years. 
 
Blackwell et al. 
2015 (186) 
USA 2009-2010 Cross-sectional 
survey 
Telephone 
survey 
Receipt of vaccine in 
previous 12 months. 
Asthmatics receiving H1N1 
vaccine: OR 1.13 (CI 0.97-
1.33). 
667 children, aged 
4 months to 17 
years, including 
asthmatics. 
 
Aigbogun et al. 
2015 (187) 
Global 2014 Systematic 
review 
NA Uptake of vaccination 
rates in high-risk children. 
Reminder letters useful in 
improving uptake but less 
evidence for telephone 
recall. 
9 studies in 
children with 
asthma, aged 6 
months to 19 
years. 
 
Mazurek et al. 
2014 (188) 
USA 2006-2009 Cross-sectional 
survey 
Telephone 
survey 
Influenza vaccination 
uptake in the preceding 
12 months. 
42.7% uptake rate. Higher 
rates in those aged 50-64 
years, unemployment and in 
those requiring urgent 
treatment for worsening 
symptoms. 
28,809 adults 
aged 18-64 years 
with work-related 
asthma. 
 
O’Halloran, 
2015 (189) 
USA 2012-2013 Cross-sectional 
survey 
Telephone 
survey 
Influenza vaccination 
uptake in the preceding 
12 months. 
Uptake rate of 29% (95% CI 
26.5-31.7%). 
8,831 adults, aged 
18-64 years with 
“pulmonary 
disease”. 
 
Lin et al. 2015 
(190) 
USA 2010-2013 Prospective 
interventional 
quality 
Utilized the “4 
pillars 
Influenza vaccination 
rates pre and post 
intervention. 
Uptake rates increased 
between 2010-11 to 2012-
2013 seasons in: Non-White 
8,250 asthmatic 
children aged 6 
months-18 years. 
This 
intervention 
reduced the 
racial 
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Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key findings Population 
Characteristics 
Limitations/
comments 
improvement 
study 
immunization 
toolkit” 
children: 46% to 61%; White 
children: 58% to 65%. 
disparity 
seen in 
vaccination 
uptake rates. 
Shoup et al. 
2015 (191) 
USA 2012-2013 Pragmatic 3-arm 
randomized 
control trial 
Three arms: 
1. Postcard 
reminder 
2. Telephone 
reminder 
3. Postcard & 
telephone 
reminder 
Change in influenza 
vaccination rate. 
No difference in intervention 
groups. 
Telephone (interactive voice 
response) calls were most 
cost-effective. 
12,285 adults 
aged 19-64 years 
with asthma or 
COPD. 
 
Buyuktiryaki et 
al. 2014 (109) 
 
 
Turkey 2010 Cross-sectional 
survey of 
parents 
Questionnaire H1N1 and seasonal 
influenza vaccination 
rates with analysis of 
demographic factors, 
asthma control 
parameters and parental 
attitudes towards 
vaccination. 
16.8 % received H1N1 
vaccine; 45.7% received 
seasonal vaccine. 
Significant factors influencing 
uptake included low 
educational background of 
parents, previous vaccination 
with seasonal influenza and 
having a family member 
vaccinated against Influenza 
A/H1N1. 
Asthma control parameters 
had no influence on uptake 
of the vaccine and physician 
recommendation (84.8%) 
was important in the 
decision-making process for 
immunization. 
625 children and 
adolescents aged 
6-18 years with 
asthma. 
 
Skupin et al. 
2015 (192) 
USA 2013 Cross-sectional 
survey 
Questionnaire Influenza vaccination 
uptake in preceding year. 
Black patients had much 
lower vaccination rates 
472 adults 
attending internal 
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Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key findings Population 
Characteristics 
Limitations/
comments 
(62.1%) than White (83.8%) 
or Asian (93.3%) patients. 
Belief in efficacy in vaccine 
and physicians 
recommendation important 
determinants in higher 
vaccination rates. 
medicine and 
allergy clinics. 
Hart et al. 2014 
(193) 
USA 2013 Cross-sectional 
survey 
Structured 
interview 
Vaccination uptake in 
previous year and 
parental intent to 
vaccinate in upcoming flu 
season. 
64% (95% CI 59-70%) 
received vaccine in previous 
year. 
37% of those parents with 
intent to vaccinate did not 
actually do so. 
224 children, aged 
6 months-17 
years, attending 
paediatric 
emergency 
department. 
Unclear what 
proportion 
are 
asthmatic at 
baseline. 
Lo, 2014 (194) USA 2013-2014 Prospective 
interventional 
quality 
improvement 
study 
Implementatio
n of influenza 
immunization 
bundle 
Vaccination rate pre- and 
post-intervention. 
Vaccination rate 
improvement from 19% (6-
26%) to 39% (9-55%). 
117 children 
attending hospital 
with asthma 
exacerbation. 
 
Regan, 2014 
(195) 
Australia 2013 Cross-sectional 
survey of 
electronic 
outpatient 
records 
NA Assessment of proportion 
of people immunized and 
estimate of vaccine 
effectiveness. 
29.7% vaccination rate in 
asthmatics vs. 52.2% in 
those with coronary heart 
disease. 
In all patients, combined 
clinical and pathological data 
suggested vaccination had 
effectiveness of 56% in 
preventing infection: OR 0.44 
(95% CI 0.24-0.79). 
2731 general 
practice patients 
with clinical and 
pathological data. 
 
ACT asthma control test; LMIC low-middle income countries; HIC high-income companies; COPD chronic obstructive pulmonary disease OR odds ration; CI confidence 
interval; NA not available;  
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Section 4. Immunogenicity of influenza vaccines in asthma  
Authors, year Country Study 
period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/co
mments 
Bae et al. 2013 
(121) 
Korea 2011-2012 
influenza 
season 
Phase 4, multi-
center, open 
label study 
TIV (H1N1, 
H3N2, B) (7.5 
μg per strain) 
Two doses in 
vaccine naïve 
children; one 
dose in 
previously 
vaccinated 
Interval 
between first 
and second 
dose not 
stated. 
Short-term 
seroconversion rates, 
seroprotection rates, 
GMT, and GMT ratio; HI 
assay Safety: local and 
systemic adverse events. 
Seroconversion and 
seroprotection rates in 
wheezers were similar to 
healthy children and 
significant for all 3 strains. 
The GMT was higher in the 
one dose-group vs. the 
two-dose group both in 
healthy children and in 
wheezers. The GMT ratio 
was significantly higher in 
healthy children than 
wheezers for the H1N1, 
H3N2 strains. No 
difference between steroid-
treated and non-treated 
wheezers. 
68 healthy 
children and 62 
recurrent 
wheezers aged 6 
months to 3 years.  
Chronic and 
high dose ICS 
excluded. No 
adjustment for 
ICS dose.  
Age 
significantly 
lower in 
healthy 
controls (1-2 y) 
than in 
wheezers (2-3 
y).  
Busse et al. 
2011 (124) 
US 2009 
influenza 
autumn 
season 
Randomized, 
open-label study 
Monovalent 
H1N1 tested at 
two doses (15 
vs. 30 μg) 
twice at 21 
days interval 
Short term rates and 
GMT of seroconversion 
and seroprotection; HI 
assay and 
microneutralization. 
The 2 dosing groups did 
not differ in seroconversion 
rates.  
In mild-to-moderate asthma 
the two doses offered 
equal seroprotection.  
In severe asthma 
seroprotection was 
significantly higher with the 
30 μg dose  
In severe asthmatics >60 
years old the 
seroprotection was 
achieved only with the 30 
μg dose The second dose 
provided no additional 
benefit.  
Adolescents and 
adults (12-79) with 
asthma; special 
subgroup > 60 
years with mild-to-
moderate and 
severe asthma 
(including use of 
OCS). 
No healthy 
controls for 
comparison. 
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Authors, year Country Study 
period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/co
mments 
Atopy, BMI, systemic 
corticosteroid or ICS dose 
had no influence on HI 
GMTs or on seroprotection 
rates. 
Pedrosa et al. 
2009 (122) 
Mexico 2001-2002 
influenza 
season 
Double-blind, 
placebo 
controlled, 
randomized 
study  
Inactivated TIV 
(H1N1, 
H3N2,B); dose 
15 μg per 
strain; twice at 
28 days 
interval 
Safety: local and 
systemic adverse events; 
lung function; short-term 
rate of seroconversion; 
HI assay. 
Significant rate of 
seroconversion after the 
first and second dose for all 
3 strains. 
Children 5-9 years 
with mild 
intermittent and 
moderate asthma. 
No healthy 
controls for 
comparison.  
Study funded 
by industry. 
Asthma 
severity 
assessed only 
as LF; no data 
on 
exacerbations. 
Subjects with a 
history of 
allergy to egg 
protein 
excluded. 
Previous 
influenza 
vaccination 
status not 
reported. 
Zuccotti, et al. 
2007 (123) 
Italy 2005-2006 
influenza 
season 
Observational 
prospective 
open label multi-
centre study 
Virosomal-
adjuvanted 
TIV (H1N1, 
H3N2,B); dose 
15 μg per 
strain; single 
dose  
Short (at one month) and 
long-term (at 6 months) 
seroconversion (≥1:40) 
and seroprotection 
(≥1:10); HI assay; both 
rate and fold-increase in 
GMT. Seroconversion 
and seroprotection in 
relation to pre-existing 
antibodies.  
Seroconversion: Both rates 
and GMT significantly high 
at both 1 and 6 months for 
all 3 strains Better GMT 
increase for the B strain in 
children 6-9 years 
compared to 3-5 years.  
Seroprotection: At one 
month satisfactory in both 
age groups, decreased 
Children with 
asthma aged 3-9 
years (subgroups 
3-5 years and 6-9 
years).  
No data on 
asthma 
severity. No 
healthy 
controls. More 
than 50% of 
children had 
pre-existing 
antibodies at 
baseline. 
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Authors, year Country Study 
period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/co
mments 
Safety: local and 
systemic adverse events. 
seroprotection for H3N2 for 
children aged 6-9 years. At 
6 months: >80% in children 
aged 6-9 years; 
significantly lower (<70%) 
in children aged 3-5 years. 
Both seroconversion and 
seroprotection to any 
specific strain significantly 
lower without pre-existing 
antibodies. 
Baseline GMTs 
were relatively 
high for all 3 
strains. 
Subjects with 
history of egg 
allergy and/or 
severe atopy 
were excluded.  
BMI body mass index; ICS inhaled corticosteroids; LF lung function; GMT geometric mean titer; HI hemagglutinin inhibition; OCS oral corticosteroids; SPT skin prick test; TIV 
trivalent influenza vaccines  
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Section 5. Efficacy of influenza vaccines in asthma 
Authors, year Country Study 
Period 
Type of study Intervention  Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
Abadoglu et al. 
2004 (125) 
Turkey Recruitme
nt: Sept -
Nov 2001. 
Follow-up 
until Mar 
2002 
Randomized, 
controlled trial 
TIV vs. no 
vaccine 
Frequency of URTI 
infections and asthma 
exacerbations during the 
winter following 
vaccination. 
URTI and asthma 
exacerbation rates similar 
between vaccinated and 
non-vaccinated groups = 
no protective effect. 
Asthmatic adults 
aged 22-84 years. 
In total: 128 
Vaccination: 86 
Nothing: 42. 
Lack of 
knowledge on 
rate of 
influenza 
epidemic in 
tested period 
or on the 
cause of URTI.  
Relatively low 
number of 
subjects 
enrolled. 
Bueving et al. 
2004 (126) 
The 
Netherlands 
1999-2000  
2000-2001 
Double-blind, 
placebo 
controlled, 
randomized 
study  
TIV vs. 
placebo 
Symptom scores (to 
detect infection); 
pharyngeal swab and 
spirometry; quality of life 
(QoL). 
In inﬂuenza-positive weeks 
of illness: - no effect was 
found for respiratory 
symptoms recorded in the 
diaries - moderately 
beneﬁcial effect on QoL 
throughout the seasons: 
No differences for 
respiratory symptoms and 
QoL. 
Asthmatic children 
aged 6-18 yrs. 
In total: 696 (296 
in 1999 -2000 and 
400 in 2000 -
2001) 347: 
inﬂuenza vaccine 
and 349 placebo.  
Relatively few 
inﬂuenza- 
positive weeks 
of illness.  
Bueving et al. 
2004 (81) 
The 
Netherlands 
1999-2000 
2000-2001 
Double-blind, 
placebo 
controlled, 
randomized 
study  
TIV vs. 
placebo 
Symptom scores (to 
detect infection)  
Pharyngeal swab.  
Blood samples for 
inﬂuenza virus -speciﬁc 
antibodies 
(immunogenicity). 
Influenza vaccination did 
not result in a significant 
reduction of the number, 
severity, or duration of 
asthma exacerbations 
caused by influenza. 
696 asthmatic 
children aged 618 
years. 
 
Fayyaz Jahani 
et al. 2012 
(127) 
Iran ND Randomized, 
placebo-
controlled study 
TIV Asthma exacerbations. Lower asthma 
exacerbation rates 
140 asthmatic 
children aged 6 to 
60 months. 
Conference 
abstract, thus 
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Authors, year Country Study 
Period 
Type of study Intervention  Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
following TIV (13%) than 
after placebo (53%). 
limited 
information. 
Fleming et al. 
2006 (128) 
Multicenter 
(UK & 
Europe) 
Oct 2002 - 
May 2003 
Reactive-CT to 
examine relative 
efficacy of CAIV-
T vs. TIV 
CAIV-T vs. TIV Surveillance for 
inﬂuenza-like symptoms. 
Nasal swab viral culture 
culture-conﬁrmed 
inﬂuenza illness. Primary 
efficacy endpoint: 
incidence of culture-
conﬁrmed inﬂuenza 
illness caused by a 
community-acquired 
subtype antigenically 
similar to that in the 
vaccine. 
CAIV-T had a signiﬁcantly 
greater relative efﬁcacy of 
35% compared with TIV. 
There was no evidence of 
a signiﬁcant increase in 
adverse pulmonary 
outcomes for CAIV-T 
compared with TIV.  
CAIV-T was well tolerated 
in children and adolescents 
with asthma.  
Asthmatic children 
aged 6 to 17 
years. 
CAIV-T (n=1114) 
TIV (n=1115). 
 
No placebo 
group, 
therefore the 
absolute 
efﬁcacy of 
each vaccine 
cannot be 
calculated. 
Ambrose et al. 
2012 (131) 
  Meta-analysis of 
two randomized, 
multinational 
trials 
CAIV-T vs. TIV Culture confirmed 
influenza illness during 
the influenza surveillance 
period. Rate of wheezing, 
hospitalization, adverse 
events. 
Children receiving LAIV 
had fewer cases of culture-
confirmed influenza illness 
than TIV recipients. 
1940 children 
aged 2-5 years 
with asthma or 
prior wheezing. 
Post hoc 
definition of 
study cohorts, 
but this is in 
part addressed 
by the sub-
population 
analysis.  
Identification of 
subjects 
asthma or 
history of 
wheezing 
relied on 
investigator 
judgment 
without 
validation.  
 TIV trivalent influenza vaccines; URTI upper respiratory tract infection; QoL quality of life; CAIV-T trivalent, cold-adapted influenza vaccine; LAIV live attenuated influenza 
vaccine 
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Section 6. Effectiveness of influenza vaccination in asthma 
Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
Christy et al. 
2004 (137) 
USA 1996-1997 Retrospective 
nested case 
control study 
Influenza 
vaccine 
Asthma-related 
hospitalization, clinic and 
emergency department 
visits. 
Adjusted OR (95% CI) 
associated with vaccine for 
asthma related:  
Hospitalization 1.9 (0.9-
3.9). 
Clinic visit 2.9 (2.0-4.1). 
Emergency department 
visits 2.0 (1.2-3.1). 
Primary care 
cohort. 400 
randomly selected 
children with 
asthma who had 
been vaccinated, 
and 400 who had 
not. Age range 1-
19 years.  
Two groups 
were not 
balanced in 
terms of 
ethnicity and 
likelihood of 
receiving 
vaccine in 
previous year, 
but this was 
taken into 
account in 
adjusted 
analysis. 
Study suggests 
that vaccine 
associated with 
worse 
outcomes. 
Patients with 
more severe 
asthma or 
those more 
likely to 
present may 
be more likely 
to have been 
vaccinated 
although 
controlling for 
these did not 
alter the 
results.  
Hak 2005 (136) Netherlands 1999-2000 Nested case 
control study  
Influenza 
vaccination 
All cause mortality, 
hospitalization, general 
practice visits for 
High-risk children <18 
years, 43% (10%-64%) of 
visits were prevented by 
All age groups 
with long term 
medical 
No separate 
analysis for 
asthma. 
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Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
influenza, pneumonia 
and other acute 
respiratory problems. 
vaccination after 
adjustment.  
High-risk adults (18-64 
years) 78% of deaths (39-
92%), 87% of 
hospitalizations (39-97%), 
and 26% of GP visits (7-
47%) were prevented.  
Elderly persons vaccine 
prevented 50% of deaths 
(95% CI, 23-68%) and 
48% of hospitalization (7- 
71%) were prevented.  
conditions. 
>75,000 patients 
in primary care 
cohort. 
Adjusted for 
previous 
medical 
utilisation and 
comorbidities.  
Herrera et al. 
2007 (138) 
USA 2003-2004 Case-control 
study 
Influenza 
vaccine 
Laboratory confirmed 
influenza report. 
Influenza: vaccine 
“efficacy” was 60% (43 -
72%) and 48% (21 -66%) 
among those without and 
with high-risk medical 
conditions. 
Influenza-related 
hospitalization: vaccine 
“efficacy” was 90% (68 -
97%) and 36% (0 -63%) 
against for persons without 
and with high-risk 
conditions. 
330 cases, 1055 
randomly 
recruited controls. 
Age range 50-64 
years. 
No separate 
data for 
asthma. 
Apparent 
effectiveness 
may be inflated 
by potential 
tendency to not 
test vaccinated 
people and 
miss an 
influenza 
diagnosis on a 
vaccinated 
patient. 
Authors say 
“efficacy” but 
study set up as 
an 
effectiveness 
study.  
Vaccine strains 
did not closely 
match 
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Limitations/ 
comments 
circulating 
influenza 
strains. 
Koshio et al. 
2014 (132) 
Japan Sept-Oct 
2010 
Survey  Vaccination 
against “ new 
type of 
influenza”: 
H1N1 pdm09. 
Report of a “new type of 
influenza”: H1N1 pdm09. 
For influenza, OR (95% CI) 
for previous vaccination 
was 0.62 (0.42-0.90) for 
younger patients ≤61 
years); among older 
patients OR was 1.38 
(0.66-2.89)  
For infection-induced 
asthma exacerbation, OR 
(95% CI) for previous 
vaccination was 1.67 (0.60-
4.66) for younger patients 
and 1.71 (0.50-5.83) for 
older ones. 
2555 adults with 
asthma. 
There may 
have been 
other 
differences 
between 
vaccinated and 
non-vaccinated 
patients that 
explained the 
difference in 
risk of 
influenza. 
Influenza 
cases were not 
laboratory 
proven. This 
study looked at 
pandemic 
rather than 
ordinary 
influenza.  
Kramarz et al. 
2001 (133) 
 
USA 1993-1996 Population 
based, 
retrospective 
cohort study  
Influenza 
vaccine 
Exacerbation of asthma. Adjusted incidence rate 
ratios of asthma 
exacerbations after 
vaccination were 0.78 
(0.55-1.10), 0.59 (0.43-
0.81), and 0.65 (0.52-0.80) 
compared with the period 
before vaccination during 
the 3 influenza seasons. 
 
Children aged 1-6 
years with asthma 
in 4 large health 
maintenance 
organizations. 
(>70,000 
patients). 
As a database-
based 
analysis, the 
asthma 
diagnostic 
labelling and 
recording of 
asthma 
exacerbations 
may not be 
completely 
accurate. 
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characteristics 
Limitations/ 
comments 
Differences in 
patients 
receiving 
vaccination 
may have 
explained the 
difference in 
exacerbations. 
Adjusted for 
asthma 
severity.  
Ong et al. 2009 
(135) 
 
USA  Survey Influenza 
vaccine 
Exacerbation of asthma 
defined by oral 
corticosteroid, hospital 
visit or emergency 
department visit. 
In the multivariate 
analyses, current influenza 
vaccination status was 
independently associated 
with significantly decreased 
OR of using oral steroids in 
the previous 12 months 
(0.29, 0.10-0.84). There 
was no association with 
hospitalization (1.39; 0.340 
-5.67) nor emergency 
department visits. 
80 children with 
asthma in a 
paediatric clinic. 
Retrospective 
approach may 
have 
introduced 
recall bias.  
Factors 
influencing 
likelihood of 
vaccination 
may have 
influenced 
likelihood of 
exacerbation, 
confounding 
the results. 
Triggers other 
than influenza 
may have been 
responsibly for 
the 
exacerbation.  
Smits et al. 
2002 (134) 
Netherlands 1995-1997 Retrospective 
cohort study  
Inactive 
influenza 
vaccination 
Physician diagnosed 
acute respiratory illness. 
Vaccine effectiveness was 
27% (-7 to 51%) after 
adjustments.  
Children with 
asthma aged 0-12 
years in primary 
care. Over 300 
Patients 
vaccinated 
may have been 
different to 
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Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments 
For those <6 years, it was 
55% (20 to 75%) compared 
with -5% (-81 to 39%) in 
older ones.  
 
patients in each 
season. 
others and 
these factors 
may have 
impacted on 
likelihood of 
developing 
respiratory 
illness. 
Adjusted for 
previous 
healthy 
utilization 
Jaiwong et al. 
2015 (196) 
Thailand June 2012 
- Aug 2013 
Cross-sectional 
non-randomized 
study 
TIV vs. no 
vaccine 
Respiratory illnesses and 
asthma-related events. 
The immunized group had 
significantly reduced: acute 
respiratory tract illnesses; 
asthma exacerbations; ER 
visits; bronchodilator usage 
and systemic steroid 
administrations; number of 
hospitalizations (p<0.001) 
and their duration (p 
<0.034). 
93 mild persistent 
asthmatic children 
aged 1-14 years 
(48 patients: 2 
doses of 
inactivated 
influenza). 
 
Non-
randomized 
study. Small 
sample size. 
Lack of info 
related to other 
confounding 
factors in 
asthmatic 
exacerbations 
such as 
compliance 
and controller 
usage, other 
virus and 
bacterial 
infections, 
pollution, 
emotional 
conditions of 
the patient. 
Yokoushi et al. 
2014 (197) 
Japan May 2009 -
Feb 2010 
Retrospective, 
cross-sectional, 
questionnaire-
based survey 
Inactivated, 
split-virus, 
non-
adjuvanted 
Vaccination rates. 
Vaccine effectiveness 
against physician-
diagnosed influenza A 
infection, and 
Comparison of positive 
influenza diagnosis rates 
between vaccinated and 
unvaccinated children with 
460 children with 
(n=144) and 
without asthma 
(n=316). 
Other 
environmental 
factors that 
may cause 
asthma 
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Limitations/ 
comments 
monovalent 
vs. no vaccine 
consecutive. asthma 
exacerbations. 
and without asthma 
showed that:  
Unvaccinated children with 
asthma had an elevated 
odds ratio (13.235; 95% CI; 
5.564-32.134). 
Treatment for asthma 
exacerbations was needed 
in a larger proportion of 
unvaccinated children. 
Vaccine effectiveness 
against physician 
diagnosed influenza was 
87% (95% CI, 78-93%) 
overall, 92% (95% CI, 81-
96%) in children with 
asthma and 81% (95% CI, 
63-91%) in children without 
asthma, respectively. 
exacerbation 
were not 
considered. No 
data on atopic 
comorbidities.
Retrospective 
study. 
Physician 
diagnosed 
influenza 
infection with 
or without a 
positive rapid 
antigen test 
result for 
influenza A 
during the 
pandemic 
period. 
ER emergency room; OR odds ratio; GP general practitioner; TIV trivalent influenza vaccine; CI confidence interval 
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Section 7. Safety of influenza vaccines in asthma  
Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key findings Population 
characteristics 
Limitations/ 
comments  
Greenhawt et 
al, 2012 (146) 
USA Oct 2010 - 
Mar 2012 
Phase 1: 
randomized, 
controlled trial. 
Phase 2: 
retrospective, 
observational 
trial 
 
Phase 1: 
Group A: 
graded 2 dose 
TIV challenge 
Group B: 
sham (saline) 
1st dose 
followed by full 
TIV dose  
Phase 2: 
participants 
who declined 
study and 
received TIV 
from their 
allergist or had 
already 
received TIV in  
primary care. 
Safety of TIV in egg-
allergic children with 
severe allergy. 
No allergic reactions were 
recorded. 
Egg-allergic 
children with 
severe allergy 
(mean age 12 
years). All patients 
had previous 
confirmed severe 
allergic reactions 
to egg. 
 
Howe et al. 
2011 (147) 
USA Phase 1: 
Oct 2004- 
Feb 2009  
Phase 2: 
2009-2010 
Phase 1: 
Retrospective, 
observational 
study. Phase 2: 
Prospective 
observational 
study. 
TIV Safety of TIV in egg-
allergic and non-allergic 
patients. 
No severe allergic 
reactions have been 
recorded. 
Children  
Miller et al. 
2003 (143) 
USA  Double-blind, 
placebo 
controlled trial. 
Influenza 
vaccine 
T-cell immune response 
to vaccine components in 
patients with asthma who 
experience 
bronchospasm. 
Increased influenza (but 
not egg) antigen-induced 
mononuclear cell 
proliferation, unrelated to 
asthma exacerbations after 
vaccine. No differences in 
cytokine production in 
response to either 
influenza or egg antigen in 
Adults, mean age 
43 years. 
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Type of study Intervention Outcome measure Key findings Population 
characteristics 
Limitations/ 
comments  
association with asthma 
exacerbations.  
Bronchospasm after 
immunization is not related 
to vaccination. 
Chung et al. 
2010 (144) 
USA 2002-2009 Retrospective, 
observational 
study 
Influenza 
vaccine 
Tolerability of the 
vaccine, defined as the 
lack of localized or 
systemic adverse 
reactions, in egg-allergic 
and non-allergic patients. 
95% of egg-allergic 
patients who received the 
vaccine skin test tolerated 
the influenza vaccine 
without any serious 
adverse reactions. 
Children, 6 
months - 18 
years. 
 
Gagnon et al. 
2010 (145) 
Canada Oct-Dec 
2009 
Prospective, 
observational 
study 
Adjuvanted 
monovalent 
2009 
pandemic 
influenza 
A/H1N1 
influenza 
vaccine 
Risk of anaphylaxis in 
children with egg allergy 
administered an 
adjuvanted monovalent 
2009 pandemic influenza 
A/H1N1 influenza 
vaccine. 
No patient had an 
anaphylactic reaction. 
Children and 
adults. 
 
Greenhawt et 
al. 2010 (149) 
USA Oct 2009- 
Feb 2010 
Controlled, 
prospective trial 
H1N1 
influenza 
vaccine 
Safety of administering 
H1N1 to egg-allergic 
patients compared with 
non-egg-allergic, 
paediatric, control 
patients. 
No significant allergic 
reactions were recorded. 
Children and 
adults aged 6 
months to 24 
years. 
 
Esposito et al. 
2008 (148) 
Italy Nov-Dec 
2007 
Prospective 
study 
Virosomal 
adjuvanted 
influenza 
vaccine 
To evaluate whether the 
virosomal adjuvanted 
influenza vaccine that 
has been shown to have 
the lowest egg protein 
content could be 
administered to children 
with even severe egg 
Administration of the whole 
vaccine was safe and well 
tolerated by all of the 
children, with no 
differences between those 
with and without egg 
allergy, or between those 
with egg allergy of different 
severity. 
Children >3 years.  
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characteristics 
Limitations/ 
comments  
allergy without any risk of 
allergic reactions. 
Castro et al. 
2001 (140) 
USA Sep-Nov 
2000 
Multicenter, 
randomized, 
double blind, 
placebo-
controlled, 
crossover trial 
TIV or placebo Safety of TIV in adults 
and children with asthma. 
The frequency of asthma 
exacerbations was similar 
in the two weeks after the 
TIV or placebo injection. 
The exacerbation rates 
were similar in subgroups 
defined according to age, 
severity of asthma, and 
other factors. 
Children and 
adults aged 3-64 
years. 
 
Baxter et al. 
2012 (141) 
USA Oct 2003 - 
March 
2008 
Prospective 
observational 
post-marketing 
study 
LAIV, TIV or 
placebo. 
Safety of LAIV, compared 
to TIV and placebo in 
children. 
Asthma/wheezing major 
adverse events were not 
statistically increased in 
LAIV recipients. No 
anaphylaxis events 
occurred. 
Children aged 5-
17 years. 
 
Ambrose et al. 
2012 (131) 
 Study 1: 
2004-2005  
Study 2: 
2002-2003 
Post-hoc 
analysis of two 
randomized, 
multinational 
trials of LAIV 
and TIV in 
children aged 6 -
71 months 
LAIV vs. TIV Safety of LAIV in 
asthmatic children 
younger than 6 years. 
Wheezing, lower 
respiratory illness, and 
hospitalization were not 
significantly increased in 
children receiving LAIV 
compared with TIV. 
Increased upper 
respiratory symptoms and 
irritability were observed in 
LAIV recipients. 
Children aged 2-5 
years. 
 
Gaglani et al. 
2008 (142) 
USA 1998-2002 Open-label field 
trial 
Trivalent LAIV Safety of the intranasal 
LAIV3 in children with 
intermitted 
wheezing/asthma. 
No increased risk for 
medically-attended acute 
respiratory illnesses, 
including asthma 
exacerbation. 
Children aged 1.5-
18 years. 
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Haber et al. 
2015 (198) 
USA LAIV4 
reports: 
2013-2014  
LAIV3 
reports: 
2010-2013 
Analysis of 
reports received 
at the “Vaccine 
Adverse Event 
Reporting 
System” 
LAIV4 vs. 
LAIV3 
Medical records were 
reviewed for non-
manufacturer serious 
reports (i.e., death, 
hospitalization, prolonged 
hospitalization, life-
threatening illness, 
permanent disability) and 
reports of selected 
conditions of interest. 
No new or unexpected 
safety concerns with 
LAIV4. The safety proﬁle of 
LAIV4 was similar to 
LAIV3. Just over 94% of 
LAIV4 reports were non-
serious and the most 
common adverse events 
were mild, self-limited 
conditions (e.g., fever, 
headache and cough). 
Children and 
adults aged 2-49 
years. 12.7 million 
doses of LAIV4 
were distributed. 
General 
limitations of 
passive 
surveillance.  
Turner et al. 
2015 (151) 
UK  Sept 2013 
- Jan 2014 
Prospective, 
multi-centre, 
open-label, 
phase IV 
intervention 
study 
LAIV Clinical symptoms after 
LAIV administration to 
estimate incidence of 1. 
Allergic reaction within 2 
hours, 2. Delayed allergic 
symptoms within 72 
hours, 3. Non-allergic 
adverse events; and 
change in nasal airway 
patency (acoustic 
rhinometry). 
LAIV appeared to be safe 
in children with egg allergy 
and additional asthma or 
recurrent wheeze. No 
systemic allergic reactions 
reported. Eight children 
had mild, self-limiting, 
potentially IgE-mediated 
allergic symptoms.   
26 (9.4%; 95% CI for 
population, 6.2% to 13.4%) 
children experienced lower 
respiratory tract symptoms 
within 72 hours, including 
13 with parent-reported 
wheeze. None of these 
episodes required medical 
intervention beyond routine 
treatment. 
282 children with 
egg allergy aged 
2-17 years. 
The egg 
protein content 
of LAIV 
batches may 
vary, thus data 
from this study 
may not be 
applicable to 
future LAIV 
stocks in which 
egg content 
may be higher. 
 TIV trivalent influenza vaccine; LAIV live attenuated influenza vaccine; CI confidence interval 
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Section 8. Antiviral treatment against influenza in patients with atshma 
Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments  
Johnston et al. 
2005 (168) 
  Randomized 
study 
Oseltamivir (2 
mg/kg) or 
placebo twice 
daily, as a 
syrup 
Effects of oseltamivir 
among influenza-infected 
children with asthma.  
Oseltamivir is safe and well 
tolerated among asthmatic 
children, may reduce 
symptom duration and 
helps improve lung function 
and reduce asthma 
exacerbations during 
influenza infection. 
Asthmatic children 
aged 6-12 years. 
Analysis was 
performed for both 
the intent-to-treat 
infected (n=179) 
and per protocol 
(n=162) 
populations. 
 
Lin et al.2006 
(162)  
China  2002-2003 Randomized, 
open-label, 
controlled trial 
Oseltamivir 7 5 
mg twice daily 
for 5 days 
(oseltamivir 
group), or 
symptomatic 
treatment 
(control group) 
within 48 h 
after symptom 
onset 
Duration and severity of 
illness in influenza-
infected patients, 
incidence of 
complications, antibiotic 
use, hospitalization and 
total medical cost. 
Oseltamivir is effective and 
well tolerated in high-risk 
patients with chronic 
respiratory or cardiac 
diseases. It can reduce the 
duration and severity of 
influenza symptoms and 
decrease the incidence of 
secondary complications 
and antibiotic use, without 
increasing the total medical 
cost. 
118 Chinese 
patients (mean 
age 48.1 years) 
with chronic 
respiratory 
diseases (chronic 
bronchitis, 
obstructive 
emphysema, 
bronchial asthma 
or bronchiectasis) 
or chronic cardiac 
disease.  
Only 8 patients 
with bronchial 
asthma. 
Cass et al. 
2000 (166) 
UK 2000 Double-blind, 
randomized, 
placebo 
controlled, two 
way cross-over 
study, 7 day 
wash out period. 
10 mg 
zanamivir as a 
dry powder 
(265 mg) or a 
placebo, twice 
daily on day 1 
and then four 
times daily 
from day 2 to 
day 14. 
Safety of Zanamivir in 
asthmatics. 
Zanamivir inhaled as a dry 
powder does not 
significantly affect the 
pulmonary function and 
airway responsiveness of 
subjects with 
mild/moderate asthma and 
therefore its use in such 
patients/subjects is not 
precluded. 
13 subjects, aged 
19-49 years, with 
asthma. 
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Shun-Shin et al. 
2009 (169) 
  Systematic 
review and 
meta-analysis of 
randomized 
controlled trials 
NA Effects of the 
neuraminidase inhibitors 
oseltamivir and zanamivir 
in treatment of children 
with seasonal influenza 
and prevention of 
transmission to children 
in households. 
Oseltamivir did not reduce 
asthma exacerbations or 
improve peak flow in 
children with asthma. 
Children aged ≤12 
years in the 
community (not 
admitted to 
hospital) with 
confirmed or 
clinically 
suspected 
influenza. 
Based on only 
one trial. 
Jefferson et al. 
2014 (170) 
  Systematic 
review  
NA Potential benefit and 
harm of oseltamivir by 
reviewing all clinical 
study reports (or similar 
document when no 
clinical study report 
exists) of randomized 
placebo controlled trials 
and regulatory 
comments. 
Ozeltamivir had no effect in 
children with asthma, but 
there was an effect in 
otherwise healthy children. 
Children and 
adults who either 
were healthy 
before exposure 
to respiratory 
agents or had a 
chronic illness 
(such as asthma, 
diabetes, 
hypertension) but 
excluding people 
with immune 
suppression. 
 
Jefferson et al. 
2014 (171) 
  Cochrane 
review 
NA Potential benefit and 
harm of neuraminidase 
inhibitors for influenza in 
all age groups by 
reviewing all clinical 
study reports of 
published and 
unpublished randomized, 
placebo-controlled trials 
and regulatory 
comments. 
For the treatment of adults, 
oseltamivir reduced the 
time to first alleviation of 
symptoms by 16.8 hours 
(95% CI 8.4-25.1, 
p<0.0001). This represents 
a reduction in the time to 
first alleviation of 
symptoms from 7 to 6.3 
days. There was no effect 
in asthmatic children, but in 
otherwise healthy children 
there was a reduction by 
All age groups. 53 
trials in Stage 1 
and 46 in Stage 2 
(formal analysis), 
including 20 
oseltamivir (9623 
participants) and 
26 zanamivir trials 
(14,628 
participants). 
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29 hours (95% CI 12-47 
hours, p=0.001).  
Watanabe, 
2013 (173) 
Japan 2009 Double-blind, 
randomized 
controlled trial 
Laninamivir 
group: singe 
inhalation of 
40 mg 
laninamivir 
and placebo 
oseltamivir 
capsules twice 
daily for 5 
days.  
Oseltamivir 
group: one 
capsule (75 
mg) of 
oseltamivir 
orally twice 
daily for 5 
days and 
laninamivir 
placebo 
powder once 
on day 1. 
Efficacy and safety of 
laninamivir octanoate, an 
inhaled neuraminidase 
inhibitor for the treatment 
of influenza patients with 
chronic respiratory 
diseases. 
Laninamivir octanoate 
showed similar efficacy 
and safety to oseltamivir in 
the treatment of influenza, 
including that caused by 
influenza A(H1N1)2009, in 
patients with chronic 
respiratory diseases. 
203 patients aged 
≥20 years. Most 
patients had 
underlying 
bronchial asthma. 
 
Kohno 2011 
(172) 
Japan Jan-May 
2009 
Multicenter, 
uncontrolled, 
randomized, 
double-blind 
study 
Peramivir 
intravenously 
administered 
at 300 or 600 
mg/day for 1 to 
5 days, as 
needed 
Efficacy and safety of the 
novel anti-influenza virus 
drug peramivir in high-
risk patients. 
In the 600 mg group about 
50% shorter duration of 
illness. In 33% of patients 
adverse drug reactions, 
described as “not 
particularly problematic 
clinically” with quick 
recovery in all cases.  
37 influenza 
patients, ≥20 
years, with risk 
factors, including 
asthma. 
5 patients with 
asthma were 
also taking 
steroids. 
Biggerstaff et 
al. 2014 (199) 
USA 2009-2010 USA state-
based, random-
digit-dialled 
none Inﬂuenza antiviral 
treatment prescription in 
influenza like illness (ILI). 
26% of respondents with 
ILI received clinical 
influenza diagnosis. Of 
these 36% received 
216,431 adults 
≥18 years, non-
institutionalized 
Data in this 
study are self-
reported and 
subject to 
 57 
Authors, year Country Study 
Period 
Type of study Intervention Outcome measure Key finding Population 
characteristics 
Limitations/ 
comments  
telephone 
survey 
antiviral treatment. Being 
younger and employed but 
not high-risk conditions, 
including asthma, were 
associated with antiviral 
treatment.  
recall and 
social 
desirability 
bias. 
Diagnosis and 
treatment are 
not verified. 
Biggerstaff et 
al. 2014 (165) 
USA 2010-2011 USA state-
based, random-
digit-dialled 
telephone 
survey  
none Inﬂuenza antiviral 
treatment prescription in 
influenza like illness (ILI). 
Among adults with a 
physician diagnosis of 
inﬂuenza, 34% received 
antiviral treatment. Having 
asthma was not associated 
with antiviral treatment. 
75,088 adults (18-
>65 years) and 
15,649 children 
(0-17 years) were 
interviewed. 
Data in this 
study are self-
reported and 
subject to 
recall and 
social 
desirability 
bias.  
Diagnosis and 
treatment arte 
not verified. 
 
COPD chronic obstructive pulmonary disease; NAI neuraminidase inhibitor; CI confidence interval. 
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Figure 1 
 
Figure 1. Global seasonal influenza vaccination policies for people with asthma. Source data obtained from following references: Europe1,2; Americas3,4; 
Africa5,6; Asia2,7-9; Oceania7. The following countries have vaccination policies for chronic disease, which includes asthma in the majority of cases: Argentina, 
Bahamas, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, Egypt, El Salvador, Fiji, Grenada, Ivory Coast, Mauritius, 
Mexico, Morocco, Panama, Paraguay, Peru, Philippines, Saint Lucia, Thailand, Trinidad and Tobago, Uruguay and Venezuela. This graphic is licenced by a 
Creative Commons Attribution-ShareAlike 3.0 Unported License: http://gunn.co.nz/map.  
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 Appendix 1 
Search strategy: Medline format 
 
1. Respiratory Hypersensitivity/ or Bronchial Hyperractivity or Asthma/ or  Status 
Asthmaticus/ 
2. (asthma or asthma exacerbation or asthma attack or acute asthma or acute asthmatic 
attack or asthmatic children or wheez*).mp. 
3. (bronchial disorder or airway reactivity or airway hyperresponsiveness or bronchial 
hyperreactivity or bronchial hyperresponsiveness or lung function or ventilatory 
function or FEV or FEF or FVC or PEF).mp. 
4. or/1-3 
5. Influenza, Human/ or Influenza vaccines/ or Influenza A virus or Influenza B virus or 
Influenzavirus C/ or Influenza A Virus, H5N1 Subtype/ or Influenza A Virus, H1N1 
Subtype/ or Influenza A Virus, H3N2 Subtype/ 
6. exp Epidemiologic Studies/ or exp Intervention Studies/ or exp Evaluation Studies/ or 
exp Comparative Studies/ or exp Follow-up Studies/ or exp Prospective Studies/ or exp 
Cohort Studies/ or exp Case-Control Studies/ or exp Cross-Sectional Studies/ 
7. (prospectiv* or cohort or birth cohort or analytical stud* or cohort stud* or case-control 
stud*or cross-sectional stud*).mp. 
8. Review literature as Topic/ or systematic review.mp. 
9. Clinical trial/ or Controlled Clinical Trial/ or Randomized Controlled Trial/ 
10. exp Placebos/ or exp Random Allocation/ or exp Double-Blind Method/ or exp Single-
Blind Method/ 
11. (trial or clinical trial or controlled clinical trial or random* or randomi?ed controlled trial 
or double-blind design or single blind design).mp. 
12. exp Survey/ or survey.mp. 
13. or/6-12 
14. 4 AND 5 AND 13 
15. limit 14 to yr=”2000-2014” 
16. limit 15 to human  
 
Search Strategy: free-field format 
(Asthma or acute asthmatic attack or status asthmaticus or wheez* or respiratory 
hypersensitivity or bronchial hyperreactivity or bronchial hyperresponsiveness or airway 
hyperreactivity or airway hyperresponsiveness) 
AND  
(Influenza, human or influenza vaccin* or influenza A virus or influenza B virus or influenzavirus 
C or influenza A virus subtype H1N1 or Influenza A virus  subtype H3N2 or Influenza A virus 
subtype H5N1) 
AND 
(Analytical stud* or epidemiologic* or compar* or evaluat* or follow-up or observation* or cohort 
stud* or case-control stud* or cross-sectional stud* or systematic review or intervention* or 
trial* or RCT or double-blind or single-blind or control* or random* or prospective or 
retrospective) 
 
 
 
 
